Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has treated the first coronary artery disease pateints in its European trial evaluating the Zomaxx drug-eluting coronary stent system.
Subscribe to our email newsletter
The European Zomaxx study is a single-arm trial that will evaluate the safety and performance of the Zomaxx zotarolimus-eluting stent in patients with single or two-vessel coronary artery disease.
The trial is important in showing that the stent can be used in patients with more complex coronary artery treatment needs.
The study will include approximately 900 patients at up to 60 sites throughout Europe with a primary endpoint of target lesion revascularization (TLR) at nine months.
“Abbott's drug-eluting stent has unique characteristics, and we look forward to studying the Zomaxx system in patients with coronary artery disease, including those suffering from multi-vessel disease,” said Dr Franz-Josef Neumann of Herz-Zentrum Bad Krozingen hospital in Baden-Wurttemberg Germany, and principal investigator in the trial.